{'fraction_non_alphanumeric': 0.02269861286254729, 'fraction_numerical': 0.01092896174863388, 'mean_word_length': 4.707434052757794, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Clinical outcome and side effects of concomitant chemoradiotherapy in the treatment of locally advanced inoperable non-small cell lung cancer: Our experiences

Background/Aim. About 1.8 million new lung cancer cases are diagnosed in the
 world every year, and about 1.6 million cases are with fatal outcome.
 Despite improvements in treatment in previous decades, the survival of
 patients with lung cancer is still poor. The five-year survival rate is
 about 50% for patients with localized disease, 20% for patients with
 regionally advanced disease, 2% for patients with metastatic disease, and
 about 14% for all stages. The median survival of patients with untreated
 NSCLC in the advanced stage is four to five months and the annual survival
 rate is only 10%. The main goal of the research is to obtain and analyze the
 results of treatment with concomitant chemotherapy in terms of its efficacy
 and toxicity in selected patients with locally advanced inoperable non-small
 cell lung cancer. Methods. The study included data analysis of 31 patients
 of both sexes who were diagnosed and pathohistologically verified with NSCLC
 in inoperable stage III and were referred by the Council for Malignant Lung
 Diseases to the Radiotherapy Department of the Military Medical Academy for
 concomitant chemoradiotherapy treatment. Upon expiry of the three-month
 period from the performed radiation treatment, the tumor resonance was
 assessed on the basis of MSCT examination of the chest and upper abdomen
 according to RECIST 1.1 criteria (Response Evaluation Criteria in Solid
 Tumors). According to the same criteria, progression-free survival (PFS) was
 also assessed every three months during the first two years, then every 6
 months or until the onset of disease symptoms, as well as overall survival
 (OS). Result. The median progression-free survival is 13 months, and the
 median overall survival is 20 months. During and immediately after RT, 9
 (29%) patients had a grade 2 or higher adverse event. Conclusion. The use of
 concomitant chemoradiotherapy in patients in the third stage of locally
 advanced inoperable non-small cell lung cancer provides a good opportunity
 for a favorable therapeutic outcome, with an acceptable degree of acute and
 late toxicity, and represents the standard therapeutic approach for selected
 patients in this stage of the disease.